1Zeki AA, Schivo M, Chan A, et al. The Asthma-COPD overlap syndrome: a common clinical problem in the elderly [J]. J Allergy (Cairo), 2011,2011:861-926.
2Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive puhnonary disease overlap syndrome: pharmacotherapeutic considerations [J]. Expert Rev Clin Pharmacol, 2013,6(2) : 197-219.
3Miravitlles M, Soler-Catalufla JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC) :Pharmacological treatment of stable COPD [J]. Aten Primaria,2012,44(7) :425-437.
4Soler-Catalufla JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD [J]. Arch Bronconeumol, 2012,48(9) :331-337.
5Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines ofthe Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care [J]. Biomcd Pap Med Fac Univ Palacky Olomouc Czech Repub, 2013,157(2) : 189-201.
6GOLD Executive Committee. Global strategy for the diagnosis, mangement,and prevention of chronic obstructive pulmonary disease (Revised 2011).
7Ai-Kassimi FA, Alhamad EH. Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go [ J ] ? Ann Thorac Med, 2013,8 ( 1 ) : 8-13.
9Marc Miravitlles.A new approach to grading and treating COPD based on clinical phenotypes:surmnary of the Spanish COPD guidelines (GesEPOC) [J]. Prim Care Respir J, 2013,22(1): 117-121.
10Hizawa N. Pharmacogeneties of chronic obstructive pulmonary disease [J]. Pharmacogenomics, 2013,14(10) : 1215-1225.
10GOLD Executive Committee. Global strategy for the diagnosis,management, and prevention of chronic obstructive pulmonarydisease (Revised 2014)[EB/OL]. [2014-05-08]. http;//www.goldcopd. com.
